Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
When used, signal modulation occurs at varying frequencies to achieve the required effects
doi:10.2147/JIR.S526158 87
Eli Lilly says that Zepbound is a dual receptor agonist that targets both GIP and GLP-1 receptors, unlike other incretins approved for obesity management, which target only GLP-1 receptors. And Novo Nordisk says that Wegovy has the broadest GLP-1 label, including indications for reducing risk of major adverse cardiovascular events in some patients and for treatment of a certain liver condition in some adults
Medical management options for heavy menstrual bleeding, as recommended by NICE, include: Levonorgestrel intrauterine system (LNG-IUS) : Often first-line treatment, reducing menstrual blood loss by up to 95% within 12 months Tranexamic acid : An antifibrinolytic agent taken during menstruation to reduce blood loss by 40-50% (caution if you have a history of blood clots) Non-steroidal anti-inflammatory drugs (NSAIDs) : Such as mefenamic acid, which can reduce flow by 20-30% and help with associated pain (use with caution if you have gastrointestinal, renal or cardiovascular conditions) Combined hormonal contraception : Can regulate cycles and reduce bleeding in suitable candidates Oral progestogens : Taken cyclically or continuously, depending on individual circumstances If you currently use a copper intrauterine device (IUD), this can contribute to heavier periods, and switching to a levonorgestrel IUS might be beneficial
